Related Experiment Video
Updated: Aug 6, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Is FAP the key to unlocking treatment for rare soft-tissue sarcomas?
1Department of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, United States.
Abstract:
Fibroblast activation protein (FAP) is highly expressed in various sarcomas, including solitary fibrous tumors (SFTs). In recent years, radiolabeled FAPI tracers have emerged as potential therapeutic targets. In SFTs with high FAP expression, 90Y-FAPI-46 demonstrated promising therapeutic efficacy. These findings highlight the potential of FAPα expression as a clinically relevant biomarker for patient selection and establish 90Y-FAPI-46-based radiopharmaceutical therapy as a promising and meaningful therapeutic option for patients with malignant SFT.
Insights
Fibroblast activation protein (FAP) is a promising target for solitary fibrous tumors (SFTs). 90Y-FAPI-46 shows therapeutic potential in FAP-expressing SFTs, offering a new treatment option.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Molecular Imaging
Background:
- Fibroblast activation protein (FAP) is significantly overexpressed in several sarcoma types, including solitary fibrous tumors (SFTs).
- FAPI tracers are emerging as valuable tools for both diagnosis and therapy in oncology.
- FAP expression levels can vary, necessitating biomarkers for targeted treatment selection.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
